Cancer Blog
- Dr. Robert Nagourney -

There has been talk of improved survival in cancer, most progress has reflected screening, early diagnosis, improved staging, and support.

One noteworthy case was a 78-year-old patient successfully treated without surgery.

Extremely rare liver cancer that mostly affects people in their twenties associated with a gene rearrangement, mostly lethal, until now.

Patients are being encouraged to contact the researchers to get biopsies and help take charge of their disease.

At the 2023 American Association for Cancer Research meeting in Orlando, we reported results of ex vivo analysis of programmed cell death.

Combining Functional Profiling with Nagourney Cancer Institute's 11,000 patient studies provides personalized cancer treatment plans.

We take a different approach to the treatment of cancer – based on profiling how our patients’ cancerous cells will respond to treatment.

After the recommended treatment, FOLFIRINOX, using his tissue we suggested new classes of drugs that target P53 and MEK/ERK.

2022 Reflection. Among our most important accomplishments in 2022 was the installation of a world-class Mass Spectrometry research program.

I applaud anything that accelerates clinical development, but once again the focus is almost exclusively genomic.

Can rare tumors offer the way forward? This optimism comes from the fact that not unlike CML, rare cancers may carry unique insights.

Fibrolamellar cancer (FLC) is a rare tumor of adolescents and young adults occurring 1 in 5 million that arises as a large mass in the live

A study in the journal Oncogene finds that pancreatic cancer may progress as a result of the loss of normal immune response. (source: ...

I recently had an interesting conversation with a physician regarding her patient with an aggressive breast cancer. A portion of tumor...

The 2013 American Society of Clinical Oncology annual meeting, held May 31 – June 1, in Chicago, afforded the opportunity to report three...

The New York Yankees catcher Yogi Berra famous quote, “Déjà vu all over again,” reminds me of the growing focus on the concept of “N-...

The American Association for Cancer Research meeting held April 6 - 10 in Washington DC, provided a scientific perspective on oncologic...

I received an inquiry via Twitter “Has anyone thought about using a sugar medium (similar to PET scans) to deliver chemo drugs?” Although...